Lumos Diagnostics (ASX: LDX) up 15% - looking much more reasonably priced now

Lumos Diagnostics (ASX: LDX) (OTCPK: LDXHF) shares are up 15% today. LDX shares have had much too much of a bounce around just recently but this particular movement seems reasonable enough. The company does indeed have that test licensed for sale now, is also recapitalised and in this latest movement has paid off the convertible notes. That last is here: “ Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has

completed the early redemption of all the remaining outstanding Convertible Notes previously issued to each of Lind Global Fund II (Lind) and SBC Global Investment Fund (SBC).” They were able to pay cash for much of it, the dilution of the other part was about 1.5% of equity - not a large amount.

There was also the share issue to recapitalise: “Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce the conclusion of its recent successful equity capital round which raised a total of A$5.44 million (before costs).”

Now, over the past couple of months there’s been a lot of volatility in the shares. As we noted about Lumos: “Lumos Diagnostics (ASX: LDX) (OTCPK: LDXHF) shares are up 500% today. LDX stock is up as a result of the FDA authorising their FebriDx test for use in the United States. Yes, this is important news, this will make a difference to the company. But 500%? It is possible to think that that might be a little bit of an over-reaction.” As it was indeed an over reaction.

Lumos

Lumos Diagnostics share price from Google Finance

As we also said when Lumos Diagnostics calmed down a bit: “Lumos Diagnostics (ASX: LDX) shares are down 50% from their peak.” Which we thought was a good and appropriate thing.

The real lesson we would take from this though is about the way that the pharma market works. All development companies are, by definition, eating shareholder capital. Until something is approved there is no revenue and without approval there is no asset to lend against. Therefore everything has to be paid for with capital. What that also means is that when something interesting happens to boost the share price then there’s going to be a share issue - to gain more of that capital at this new and lower price.

Which is something that we should keep in mind when playing in this sector. Sure, share prices can soar, as here, on approvals. But they’re near certainly going to be followed by a share issue and a consonant fall in the share price.